Sumitomo sales reach five-year high thanks to latest all-electric IntElect machines French pharmaceuticals company, UPSA, has acquired a Stratasys Fortus 3D printer, working to revitalize its manufacturing workshop whilst reducing costs by 95 percent on some processes, with Stratasys additive manufacturing.
The impact on UPSA’s operations has been immediate and positive, with the investment paying for itself within just one year of arrival. UPSA, part of Bristol-Myers Squibb, identified additive manufacturing as a means to revitalize its in-house workshop and attract the next generation of technicians. UPSA also sees the technology as the key to overcoming production-line challenges, which had previously limited the number of machine parts it was able to make via traditional manufacturing methods.
Rédéric Tremoulet, 3D Printer Manager and Mathieu Dumora, UPSA Project Manager, holding 3D printed production tools for the camera mounts Mathieu Dumora, Project Manager in UPSA’s Technical Department, said: “We identified 3D printing as a possible solution to our needs and made an estimate of all the parts we could 3D print to see if we could save manufacturing costs and reduce our stock of parts. We quickly realized that by using 3D printed parts, we could reduce part weight by 70 percent, which reduces machine wear-and-tear, and has a big impact on productivity and machine longevity.” UPSA bought a Stratasys Fortus 450mc Production 3D Printer, which proved an immediate success by quickly delivering substantial efficiency savings for critical parts replacement.
Read more: Stratasys 3D printer for thermoplastic resin and ABS-M30i biocompatible parts aids French pharma firm to recoup costs …
thumbnail courtesy of eppm.com